2026-04-14T06:46:39Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/134372025-10-24T10:33:50Zcom_2072_451665com_2072_378040com_2072_378070col_2072_451666col_2072_378092

Real-world evidence of Carfilzomib, Lenalidomide and Dexamethasone (KRD) Scheme in patients with relapsed / refractory multiple myeloma Garcia‑Guiñon, Antoni Andrea Charry, Paola Jimenez, María Sarrà-Escandell, Josep Delgado, Izarbe Segura de la Torre, Laura Garcia-Pintos, Marta Gonzalez, Yolanda Sancho, Esther Senín, Alicia [Garcia-Guiñon A, Delgado I] Servei d'Hematologia, Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain. [Charry PA] Servei d'Hematologia, Hospital Clínic, Barcelona, Spain. Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. Universitat de Barcelona, Barcelona, Spain. [Jimenez M] Servei d'Hematologia, Hospital Universitari Vall d’Hebron, Barcelona, Spain. [Sarra J] Servei d'Hematologia, Hospital Universitari Joan XXIII Tarragona, Spain. Institut Català d'Oncologia Camp de Tarragona (ICO), Tarragona, Spain. [Segura de la Torre L] Servei d'Hematologia, Hospital Universitari Parc Taulí, Sabadell, Spain. [Garcia-Pintos M] Servei d'Hematologia, Consorci Sanitari Terrassa, Terrassa, Spain. [Gonzalez Y] Servei d'Hematologia, Hospital Universitari Josep Trueta Girona, Spain. Institut Català d'Oncologia Girona (ICO), Girona, Spain. [Senín A] Servei d'Hematologia, Hospital Universitari Germans Trias I Pujol, Badalona, Spain. Institut Català d'Oncologia Can Ruti (ICO), Badalona, Spain. [Sancho E] Servei d'Hematologia, Hospital General de Granollers, Granollers, Spain Hospital General de Granollers Mieloma múltiple Quimioteràpia combinada Anàlisi de supervivència (Biometria) DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Plasma Cell::Multiple Myeloma ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Clinical Protocols::Antineoplastic Protocols::Antineoplastic Combined Chemotherapy Protocols Other subheadings::Other subheadings::Other subheadings::/administration & dosage CHEMICALS AND DRUGS::Polycyclic Compounds::Fused-Ring Compounds::Steroids::Pregnanes::Pregnadienes::Pregnadienetriols::Dexamethasone Other subheadings::Other subheadings::Other subheadings::/adverse effects CHEMICALS AND DRUGS::Organic Chemicals::Carboxylic Acids::Acids, Carbocyclic::Phthalic Acids::Phthalimides::Lenalidomide Other subheadings::Other subheadings::Other subheadings::/adverse effects ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias de células plasmáticas::mieloma múltiple TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::protocolos clínicos::protocolos antineoplásicos::protocolos de quimioterapia antineoplásica combinada Otros calificadores::Otros calificadores::Otros calificadores::/administración & dosificación COMPUESTOS QUÍMICOS Y DROGAS::compuestos policíclicos::compuestos con anillos de fusión::esteroides::pregnanos::pregnadienos::pregnadienotrioles::dexametasona Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos COMPUESTOS QUÍMICOS Y DROGAS::compuestos orgánicos::ácidos carboxílicos::ácidos carbocíclicos::ácidos ftálicos::ftalimidas::lenalidomida Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos Carfilzomib, lenalidomide and dexamethasone; Real-world; Relapsed/refractory multiple myeloma Carfilzomib, lenalidomida y dexametasona; Mundo real; Mieloma múltiple recidivante/refractario Carfilzomib, lenalidomida i dexametasona; Món real; Mieloma múltiple recidivant/refractari Carfilzomib, lenalidomide and dexamethasone (KRd) is still a widely used treatment option for patients with relapsed / refractory multiple myeloma (RRMM). However, there is limited real-world evidence. Here we evaluated the efficacy and safety of KRd in patients with RRMM treated following the standard clinical practice of the hospitals in the Catalan region. This was a retrospective, observational study. The objective response rate (ORR) according to IMWG criteria was the primary endpoint. Secondary endpoints included progression-free survival (PFS) and overall survival (OS). The study planned to include at least 100-150 patients. In total 194 patients were included. Median age was 64 years (range: 40-88) and 56% were male. All patients had received bortezomib. Additionally, 89 patients (46%) had received thalidomide and 29 (15%) lenalidomide. The ORR was 73% (95% CI: 66-79), with 72 patients (37%) having ≥ CR. The ORR was influenced by ISS score, number of previous treatments and exposure to lenalidomide. The median PFS was 26 months and 2-years OS rate 70%. The ISS stage and LDH levels were independent prognostic factors of survival. In conclusion, the KRd scheme led to a good effectiveness comparable safety profile to the phase III clinical trial in patients with RRMM. 2025-07-22T10:52:57Z 2025-07-22T10:52:57Z 2025-02 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Garcia-Guiñon A, Charry PA, Jimenez M, Sarra J, Delgado I, Segura de la Torre L, et al. Real-world evidence of Carfilzomib, Lenalidomide and Dexamethasone (KRD) Scheme in patients with relapsed / refractory multiple myeloma. Ann Hematol. 2025 Feb;104(2):1177-1186. 0939-5555 http://hdl.handle.net/11351/13437 10.1007/s00277-025-06240-1 39954075 http://hdl.handle.net/11351/13437 eng Annals of Hematology;104(2) https://doi.org/10.1007/s00277-025-06240-1 Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess application/pdf Springer Scientia